Low-dose ionizing radiation may be a promising, although possibly controversial, therapy for Alzheimer’s disease, according to the researchers behind a small new pilot study.
The new trial, called EMBARK, will re-dose patients who took part in the drug’s earlier clinical studies. It is expected to be one of the largest clinical trials in Alzheimer’s disease, the company says.
The experimental Alzheimer’s drug aducanumab is not ready for federal approval in June, advisers to the Food and Drug Administration say in a new JAMA editorial.
California and Florida prepare to open vaccine access to all adults … Common Alzheimer’s treatment linked to slower cognitive decline …Flu shot associated with fewer, less severe COVID cases … Biden administration adds $10 billion to vaccine effort … What is a viral variant anyway? Expert explains in brief video
The great prevalence of mild disease underscores the need for interventions that may slow decline or prevent progression in dementia, researchers contend.
If approved by the FDA, aducanumab would be the first-ever drug marketed to slow progression of the brain-wasting disease, according to its developer. But an advisory committee was unconvinced of the drug’s efficacy, voting 8 to 1 against recommending approval.
Documents released on Wednesday show that the agency’s staff members already are enthusiastic about the drug’s prospects. If approved, aducanumab could be the first drug on the market to slow Alzheimer’s progression.
Millions of Medicare records will be used to analyze how two drug classes commonly used to treat Alzheimer’s may lead to a ‘prescription cascade’ when taken together.
The experimental blood test rivals the accuracy of standard diagnostic methods and may soon prove to be a cost-effective, accessible tool in the clinical setting, according to some in the scientific community.
The discovery of new biomarkers — along with a focus on repurposed drugs — are optimistic signs for Alzheimer’s research, according to a five-year analysis.
